GNLX Stock Price, GENELUX CORPORATION Quote, Chart

Market Summary

USD3.48+0.20

Market Closed

6.10%

GNLX Alerts

1 major insider sales recently.

GNLX Stock Price

View Fullscreen

GNLX RSI Chart

GNLX Valuation

Market Cap

93.5M

Price/Earnings (Trailing)

-3.3

Price/Sales (Trailing)

549.95

Price/Free Cashflow

-4.39

GNLX Price/Sales (Trailing)

GNLX Profitability

Return on Equity

-145.31%

Return on Assets

-101.45%

Free Cashflow Yield

-22.78%

GNLX Fundamentals

GNLX Revenue

Revenue (TTM)

170.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

GNLX Earnings

Earnings (TTM)

-28.3M

Earnings Growth (Yr)

-93.62%

Earnings Growth (Qtr)

-26.6%

Breaking Down GNLX Revenue

Last 7 days

4.8%

Last 30 days

-33.7%

Last 90 days

-64.5%

How does GNLX drawdown profile look like?

GNLX Financial Health

Current Ratio

3.69

GNLX Investor Care

Shares Dilution (1Y)

9.42%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.3M	5.6M	2.9M	170.0K
2022	0	0	0	11.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GENELUX CORPORATION

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	szalay aladar	sold	-109,161	3.3018	-33,061	-
Apr 30, 2024	szalay aladar	sold	-63,980	3.1157	-20,535	-
Apr 29, 2024	szalay aladar	sold	-20,792	3.2473	-6,403	-
Apr 24, 2024	szalay aladar	sold	-28,250	3.5033	-8,064	-
Apr 23, 2024	szalay aladar	sold	-76,799	3.4909	-22,000	-
Apr 22, 2024	szalay aladar	sold	-50,597	3.5306	-14,331	-
Apr 17, 2024	szalay aladar	sold	-84,424	3.7131	-22,737	-
Apr 16, 2024	szalay aladar	sold	-171,802	3.529	-48,683	-
Dec 15, 2023	yu yong	sold	-428,180	13.1606	-32,535	vp, clinical trial operations
Dec 13, 2023	thomas john	sold	-120,387	13.3763	-9,000	-

Which funds bought or sold GNLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Blue Trust, Inc.	added	7.22	-162,317	63,683	-%
Apr 30, 2024	WOODWARD DIVERSIFIED CAPITAL, LLC	added	0.34	-8,179,900	6,982,700	4.34%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	25.00	25.00	-%
Apr 29, 2024	BENJAMIN F. EDWARDS & COMPANY, INC.	sold off	-100	-2,000	-	-%
Apr 26, 2024	LifeSteps Financial, Inc.	added	26.57	-205,555	284,907	0.22%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-9.72	-441,772	312,533	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-1,228	1,042	-%
Apr 23, 2024	Global Retirement Partners, LLC	added	100	550	32,150	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-69.76	-25,000	4,000	-%

Are Funds Buying or Selling GNLX?

Are funds buying GNLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GNLX

No. of Funds

GNLX Alerts

1 major insider sales recently.

Unveiling GENELUX CORPORATION's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 02, 2024	szalay aladar	15.7%	4,185,305	SC 13G

Recent SEC filings of GENELUX CORPORATION

View All Filings

Date Filed	Form Type	Document
May 01, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading
Apr 15, 2024	144/A	144/A
Apr 11, 2024	144	Notice of Insider Sale Intent
Apr 09, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	10-K	Annual Report
Feb 13, 2024	EFFECT	EFFECT

Peers (Alternatives to GENELUX CORPORATION)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

GENELUX CORPORATION News

Latest updates

GENELUX CORPORATION Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	-100.0%	-	2,200	4,400	6,600	8,800	11,000
Operating Expenses	31.9%	7,001	5,307	5,395	6,632	3,162	4,656
S&GA Expenses	14.2%	2,841	2,488	2,452	3,787	694	2,242
R&D Expenses	47.6%	4,160	2,819	2,943	2,845	2,468	2,414
Interest Expenses	-100.0%	-	22.00	-	50.00	40.00	39.00
Income Taxes	-	-	-	-	-	-	1,100
Earnings Before Taxes	100.0%	-	-5,345	-	-	-	6,009
Net Income	-26.6%	-6,767	-5,345	-5,821	-10,364	-3,495	4,909
Net Income Margin	-1825.3%	-166.45*	-8.65*	-2.63*	-1.41*	-0.47*	-
Free Cashflow	-96.8%	-7,153	-3,634	-5,814	-4,699	-1,518	-2,503

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Assets	-18.1%	28.00	34.00	31.00	15.00	6.00
Current Assets	-22.4%	24.00	31.00	29.00	12.00	2.00
Cash Equivalents	-68.5%	9.00	30.00	27.00	10.00	0.00
Net PPE	14.5%	1.00	1.00	1.00	1.00	1.00
Liabilities	-16.2%	8.00	10.00	9.00	12.00	41.00
Current Liabilities	-25.1%	7.00	9.00	8.00	11.00	32.00
Long Term Debt	-	-	-	-	-	9.00
LT Debt, Non Current	-	-	-	-	-	9.00
Shareholder's Equity	-19.0%	19.00	24.00	22.00	3.00	-35.78
Retained Earnings	-3.2%	-221	-214	-209	-203	-189
Additional Paid-In Capital	0.9%	241	239	232	207	154
Shares Outstanding	0.5%	27.00	27.00	26.00	25.00	9.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)								(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-105.8%	-6,910	-3,357	-5,418	-4,590	-1,518	-2,470	-2,408	2,825
Share Based Compensation	197.7%	1,533	515	240	227	43.00	1,703	297	372
Cashflow From Investing	-4933.2%	-13,942	-277	-396	-109	-	-33.00	-1.00	-15.00
Cashflow From Financing	-93.7%	401	6,363	22,616	14,640	545	-329	-564	-130

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GNLX Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 170	$ 11,068
Operating expenses:
Research and development	12,767	9,078
General and administrative	11,568	5,003
Total operating expenses	24,335	14,081
Loss from operations	(24,165)	(3,013)
Other income (expenses):
Interest income	244
Interest expense	(173)	(1,150)
Debt discount amortization	(649)	(258)
Financing costs	(3,152)
Debt extinguishment costs	(402)
Gain on forgiveness of PPP loan payable		314
Total other income (expenses), net	(4,132)	(1,094)
Loss before provision for foreign income taxes	(28,297)	(4,107)
Provision for foreign income taxes		(1,100)
NET LOSS	$ (28,297)	$ (5,207)
LOSS PER COMMON SHARE - BASIC	$ (1.16)	$ (0.57)
LOSS PER COMMON SHARE - DILUTED	$ (1.16)	$ (0.57)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC	24,429,278	9,116,489
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED	24,429,278	9,116,489

GNLX Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 9,418	$ 397
Short-term investments	13,773
Prepaid expenses and other current assets	1,012	1,495
Total Current Assets	24,203	1,892
Property and equipment, net	1,170	644
Right of use assets	2,428	1,335
Deferred offering costs		1,568
Other assets	92	92
Total Other Assets	3,690	3,639
TOTAL ASSETS	27,893	5,531
Current Liabilities
Accounts payable and accrued expenses	3,784	6,775
Accrued payroll and payroll taxes	2,117	2,852
Accrued interest payable		1,178
Accrued interest payable - director and shareholders		3,817
Deferred revenue		170
Warrant liabilities		169
Lease liability, current portion	653	266
Notes payable - shareholders, net of debt discount of $108 in 2022		992
Convertible notes payable - shareholders, current portion		15,407
Total Current Liabilities	6,554	31,626
Long-term Liabilities
Lease liability, long-term portion	1,866	1,164
Convertible notes payable, net of debt discount of $541 in 2022		8,524
Total Long-term Liabilities	1,866	9,688
Total Liabilities	8,420	41,314
Shareholders’ Equity (Deficit)
Preferred stock, Series A through K, par value $0.001, 10,000,000 shares authorized as of 12/31/2023 and 29,927,994 authorized as of 12/31/2022; no shares and 22,094,889 shares issued and outstanding, respectively;		22
Common stock, par value $0.001, 200,000,000 shares authorized; 26,788,986 and 9,126,726 shares issued and outstanding, respectively	27	9
Treasury stock, 433,333 shares, at cost	(433)	(433)
Additional paid-in capital	241,389	154,401
Accumulated other comprehensive income	14	2
Accumulated deficit	(221,524)	(189,784)
Total Shareholders’ Equity (Deficit)	19,473	(35,783)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)	$ 27,893	$ 5,531

About GENELUX CORPORATION

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

CEO	Mr. Thomas Zindrick J.D.
WEBSITE	genelux.com
INDUSTRY	Biotechnology
EMPLOYEES	20

GENELUX CORPORATION Frequently Asked Questions

What is the ticker symbol for GENELUX CORPORATION? What does GNLX stand for in stocks?

GNLX is the stock ticker symbol of GENELUX CORPORATION. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GENELUX CORPORATION (GNLX)?

As of Thu May 02 2024, market cap of GENELUX CORPORATION is 93.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GNLX stock?

You can check GNLX's fair value in chart for subscribers.

What is the fair value of GNLX stock?

You can check GNLX's fair value in chart for subscribers. The fair value of GENELUX CORPORATION is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GENELUX CORPORATION is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GNLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GENELUX CORPORATION a good stock to buy?

The fair value guage provides a quick view whether GNLX is over valued or under valued. Whether GENELUX CORPORATION is cheap or expensive depends on the assumptions which impact GENELUX CORPORATION's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GNLX.

What is GENELUX CORPORATION's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, GNLX's PE ratio (Price to Earnings) is -3.3 and Price to Sales (PS) ratio is 549.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GNLX PE ratio will change depending on the future growth rate expectations of investors.